Loading...

We've got a brand new version of Simply Wall St! Try it out

China SXT Pharmaceuticals

Nasdaq:SXTC
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SXTC
Nasdaq
$26M
Market Cap
  1. Home
  2. US
  3. Household
Company description

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The last earnings update was 90 days ago. More info.


Add to Portfolio Compare Print
  • China SXT Pharmaceuticals has significant price volatility in the past 3 months.
SXTC Share Price and Events
7 Day Returns
-18.1%
NasdaqCM:SXTC
2.2%
US Personal Products
0.3%
US Market
1 Year Returns
-
NasdaqCM:SXTC
20.5%
US Personal Products
12.5%
US Market
SXTC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
China SXT Pharmaceuticals (SXTC) -18.1% -6.9% -62.9% - - -
US Personal Products 2.2% -1.1% 5.5% 20.5% 54.3% 59.2%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • No trading data on SXTC.
  • No trading data on SXTC.
Price Volatility
Industry
5yr Volatility vs Market

SXTC Value

 Is China SXT Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for China SXT Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $0.9498.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for China SXT Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are China SXT Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:SXTC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.07
NasdaqCM:SXTC Share Price ** NasdaqCM (2019-11-12) in USD $0.95
United States of America Personal Products Industry PE Ratio Median Figure of 21 Publicly-Listed Personal Products Companies 17.08x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of China SXT Pharmaceuticals.

NasdaqCM:SXTC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SXTC Share Price ÷ EPS (both in USD)

= 0.95 ÷ 0.07

12.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China SXT Pharmaceuticals is good value based on earnings compared to the US Personal Products industry average.
  • China SXT Pharmaceuticals is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does China SXT Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqCM:SXTC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 12.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
10.8%per year
United States of America Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.56x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for China SXT Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on China SXT Pharmaceuticals's assets?
Raw Data
NasdaqCM:SXTC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.49
NasdaqCM:SXTC Share Price * NasdaqCM (2019-11-12) in USD $0.95
United States of America Personal Products Industry PB Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.65x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqCM:SXTC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SXTC Share Price ÷ Book Value per Share (both in USD)

= 0.95 ÷ 0.49

1.94x

* Primary Listing of China SXT Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China SXT Pharmaceuticals is good value based on assets compared to the US Personal Products industry average.
X
Value checks
We assess China SXT Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. China SXT Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SXTC Future Performance

 How is China SXT Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover China SXT Pharmaceuticals, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is China SXT Pharmaceuticals expected to grow at an attractive rate?
  • China SXT Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • China SXT Pharmaceuticals's earnings growth is positive but not above the United States of America market average.
  • Unable to compare China SXT Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:SXTC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:SXTC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 10.8%
United States of America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:SXTC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:SXTC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 7 0 2
2018-12-31 7 2 1
2018-09-30 7 1 1
2018-06-30 7 2 1
2018-03-31 7 2 1
2017-12-31 7 0 1
2017-03-31 5 0 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • China SXT Pharmaceuticals's earnings are expected to grow by 10.8% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if China SXT Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:SXTC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from China SXT Pharmaceuticals Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SXTC Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.07
2018-12-31 0.07
2018-09-30 0.07
2018-06-30 0.06
2018-03-31 0.06
2017-12-31 0.07
2017-03-31 0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if China SXT Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess China SXT Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
China SXT Pharmaceuticals has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SXTC Past Performance

  How has China SXT Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare China SXT Pharmaceuticals's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if China SXT Pharmaceuticals's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare China SXT Pharmaceuticals's 1-year earnings growth to the 5-year average due to insufficient past data.
  • China SXT Pharmaceuticals's earnings growth has exceeded the US Personal Products industry average in the past year (29.6% vs 19.9%).
Earnings and Revenue History
China SXT Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from China SXT Pharmaceuticals Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SXTC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 7.01 1.54 2.84
2018-12-31 6.90 1.45 2.61
2018-09-30 7.05 1.39 2.51
2018-06-30 7.03 1.29 2.14
2018-03-31 7.02 1.19 1.77
2017-12-31 6.74 1.38 1.37
2017-03-31 4.88 1.19 0.71
2016-03-31 3.72 0.14 0.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • China SXT Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • China SXT Pharmaceuticals used its assets more efficiently than the US Personal Products industry average last year based on Return on Assets.
  • China SXT Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess China SXT Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
China SXT Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SXTC Health

 How is China SXT Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up China SXT Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • China SXT Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • China SXT Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of China SXT Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from China SXT Pharmaceuticals Company Filings, last reported 7 months ago.

NasdaqCM:SXTC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 11.11 2.74 9.13
2018-12-31 11.11 2.74 9.13
2018-09-30 3.97 0.38 0.22
2018-06-30 3.97 0.38 0.22
2018-03-31 3.29 0.39 0.56
2017-12-31 3.00 0.30 0.04
2017-03-31 1.85 0.30 0.07
2016-03-31 0.74 0.38 0.01
  • China SXT Pharmaceuticals's level of debt (24.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if China SXT Pharmaceuticals's debt level has increased without past 5-year debt data.
  • Debt is not well covered by operating cash flow (8.7%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 342x coverage).
X
Financial health checks
We assess China SXT Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. China SXT Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SXTC Dividends

 What is China SXT Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from China SXT Pharmaceuticals dividends.
If you bought $2,000 of China SXT Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate China SXT Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate China SXT Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:SXTC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as China SXT Pharmaceuticals has not reported any payouts.
  • Unable to verify if China SXT Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of China SXT Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as China SXT Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess China SXT Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can China SXT Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. China SXT Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SXTC Management

 What is the CEO of China SXT Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Albert Zhou
COMPENSATION $17,859
AGE 27
TENURE AS CEO 2.3 years
CEO Bio

CEO Compensation
  • Albert's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Albert's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the China SXT Pharmaceuticals management team in years:

2.7
Average Tenure
45
Average Age
  • The tenure for the China SXT Pharmaceuticals management team is about average.
Management Team

Albert Zhou

TITLE
Chairman of the Board & CEO
COMPENSATION
$18K
AGE
27
TENURE
2.3 yrs

Alex Shi

TITLE
Chief Financial Officer
COMPENSATION
$27K
AGE
48
TENURE
2.7 yrs

Jingzhen Deng

TITLE
Chief Scientific Officer & COO
COMPENSATION
$27K
AGE
59
TENURE
2.7 yrs

Jun Zheng

TITLE
Executive Director
AGE
42
Board of Directors Tenure

Average tenure and age of the China SXT Pharmaceuticals board of directors in years:

0.8
Average Tenure
49
Average Age
  • The average tenure for the China SXT Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Albert Zhou

TITLE
Chairman of the Board & CEO
COMPENSATION
$18K
AGE
27

Jun Zheng

TITLE
Executive Director
AGE
42
TENURE
0.8 yrs

Wenwei Fan

TITLE
Independent Director
AGE
49
TENURE
0.8 yrs

Tulin Lu

TITLE
Independent Director
AGE
56
TENURE
0.8 yrs

Junsong Li

TITLE
Independent Director
AGE
55
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess China SXT Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. China SXT Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SXTC News

Simply Wall St News

SXTC Company Info

Description

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. It serves pharmaceutical distributors, pharmaceutical companies, pharmacies, and hospitals. The company was founded in 2005 and is based in Taizhou, China.

Details
Name: China SXT Pharmaceuticals, Inc.
SXTC
Exchange: NasdaqCM
Founded: 2005
$25,558,457
26,909,305
Website: http://www.sxtchina.com
Address: China SXT Pharmaceuticals, Inc.
No.178 North Taidong Road,
Taizhou,
Jiangsu Province, 225300,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SXTC Common Stock Nasdaq Capital Market US USD 04. Jan 2019
DB 2RY Common Stock Deutsche Boerse AG DE EUR 04. Jan 2019
Number of employees
Current staff
Staff numbers
96
China SXT Pharmaceuticals employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/13 00:36
End of day share price update: 2019/11/12 00:00
Last earnings filing: 2019/08/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.